Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109726 | 1.00 | ALDH1A1 (0.66) | ALDH1A1GLATDP1GRM2TSHR | |
| SCHEMBL29425003 | 1.00 | ALDH1A1 (0.66) | ALDH1A1GLATDP1GRM2TSHR | |
| SCHEMBL22357196 | 0.86 | ALDH1A1 (0.78) | ALDH1A1GLATDP1TSHRTP53 | |
| SCHEMBL679937 | 0.86 | ALDH1A1 (0.78) | ALDH1A1GLATDP1TSHRTP53 | |
| SCHEMBL5513145 | 0.86 | ALDH1A1 (0.57) | ALDH1A1GLATDP1GRM2TSHR | |
| SCHEMBL5524768 | 0.86 | ALDH1A1 (0.57) | ALDH1A1GLATDP1GRM2TSHR | |
| SCHEMBL2335627 | 0.86 | ALDH1A1 (0.57) | ALDH1A1GLATDP1GRM2TSHR | |
| SCHEMBL29847902 | 0.86 | ALDH1A1 (0.57) | ALDH1A1GLATDP1GRM2TSHR | |
| SCHEMBL19612301 | 0.84 | ALDH1A1 (0.56) | ALDH1A1GLATDP1GRM2TSHR | |
| SCHEMBL19612516 | 0.83 | ALDH1A1 (0.62) | ALDH1A1GLATDP1GRM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262226-A1 | METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR | ARTESIAN THERAPEUTICS, INC. (CA) | 2008-10-23 | — | — | US | disclosed |
| US-20080262226-A1 | METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR | ARTESIAN THERAPEUTICS, INC. (CA) | 2008-10-23 | — | — | US | disclosed |
| WO-2008083054-A2 | LIGANDS FOR CARDIAC BETA1 ADRENOCEPTOR FOR IMAGING CONGESTIVE HEART FAILURE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008058198-A1 | METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR | CARDIOME PHARMA CORP. (CA) | 2008-05-15 | — | — | WO | disclosed |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-6699860-B2 | ADRENERGIC BLOCKING AGENTS | BAYER PHARMACEUTICALS CORPORATION | 2004-03-02 | — | — | US | disclosed |
| EP-1343778-A2 | DI-SUBSTITUTED AMINOMETHYL CHROMAN DERIVATIVE BETA-3 ADRENORECEPTOR AGONISTS | Bayer Corporation (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030078258-A1 | Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-04-24 | — | — | US | disclosed |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
| WO-2002048134-A2 | DI-SUBSTITUTED AMINOMETHYL CHROMAN DERIVATIVE BETA-3 ADRENORECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2002-06-20 | — | — | WO | disclosed |
| EP-1140849-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040560-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
| US-5204463-A | Substituted methoxyphenyl-4,5 dihydro-3(2H)-pridazinones having cardiotonic and beta blocking activities | GLAXO INC. (US) | 1993-04-20 | — | — | US | disclosed |
| US-5153209-A | Cardiotonic agents | GLAXO INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5096904-A | Congestive heart failure | GLAXO INC. (US) | 1992-03-17 | — | — | US | disclosed |
| US-5053338-A | Hydrolysis of ester to obtain an optically enriched mixture of a phenol enantiomer | GLAXO INC. (US) | 1991-10-01 | — | — | US | disclosed |
| US-5051431-A | For treatment of congestive heart failure | GLAXO INC. (US) | 1991-09-24 | — | — | US | disclosed |
| EP-0419286-A2 | Pyridone nitriles useful in treating cardiovascular disease | GLAXO WELLCOME INC. (US) | 1991-03-27 | — | — | EP | disclosed |
| EP-0412814-A2 | Pyridazinones having cardiotonic and beta blocking activity | GLAXO WELLCOME INC. (US) | 1991-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | ALDH1A1 275/4885GLA 2048/4885TDP1 3342/4885 |
| US-20080262226-A1 | METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR | ADRB2, ADRB3, ADRB1 | ALDH1A1 1093/4885GLA 1252/4885TDP1 1223/4885 |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB2, ADRB1, ADRB3 | ALDH1A1 578/4885GLA 2527/4885TDP1 3843/4885 |
| US-20030078258-A1 | Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists | ADRB3, ADRB1, ADRB2 | ALDH1A1 1696/4885GLA 3504/4885TDP1 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.